Enhanced Recovery After Surgery for Emergency Caesarean Deliveries
NCT ID: NCT03518463
Last Updated: 2018-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
160 participants
INTERVENTIONAL
2017-06-20
2017-11-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Enhanced Recovery After Emergency Cesarean Section: A Comparative Study Assessing Postoperative Recovery and Outcomes
NCT07242924
Comparison of Outcome Between (ERACS) Versus Traditional Methods in Elective CS
NCT06225557
Outcomes of Enhanced Recovery After Cesarean (ERAC) Protocol
NCT05786352
Enhanced Recovery Versus Conventional Care After Cesarean Section
NCT04360382
Enhanced Recovery After Surgery (ERAS) Protocol in Elective Cesarean Sections
NCT07104890
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
ERAS arm received;
Preoperative:1. Intravenous (IV) cefazoline 1g 2. IV metoclopromide 10mg, dexamethasone 8mg, ranitidine 150mg
Intraoperative: 1. Hyperbaric bupivacaine 10-15mg plus intrathecal morphine 100mcg 2. Adrenaline 100mcg in 500ml of ringers lactate 3. Individualized goal directed fluid therapy 4. Reinforced counseling and education 5. wound infiltration with isobaric bupivacaine 2mg/kg 6. Rectal diclofenac 100mg and misoprostol 400mcg stat
Postoperative:
1. Feeding within 1 hour
2. urethral catheter removal at 6-8 hours
3. Mobilization at 8-10 hours
4. A single fixed dose combination of ibuprofen 400 mg and paracetamol 500 mg 8 hourly
5. Tablets Amoxicillin-clavulunate 850mg 12 hourly
Enhanced recovery after surgery (ERAS)
The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
Control
Standard care arm received;
1. IV ceftriaxone 2g or ampiclox 2g
2. Anesthetists administered IV fluids, vasopressors, and managed hypothermia based on their clinical impressions.
3. Oral feeding and breastfeeding were allowed any time after transfer to postnatal ward.
4. Urethral catheters were removed between 12-24 hours after surgery.
5. Ward nurses and obstetricians made decisions regarding treatment without study staff input or oversight.
Enhanced recovery after surgery (ERAS)
The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enhanced recovery after surgery (ERAS)
The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mbarara University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Baluku Moris, MD
Role: PRINCIPAL_INVESTIGATOR
Mbarara University of Science and Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mbarara university of Science and Technology
Mbarara, , Uganda
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MUST 0606/2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.